top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Valneva SE - American Depositary Shares (NQ:VALN)

5.580 +0.170 (+3.14%)
Delayed Quote Updated: 2:51 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Valneva SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 ↗
Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026. 
Via Benzinga
News headline image
US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events ↗
FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment. 
Via Benzinga
Topics Death
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Insights Ahead: Valneva's Quarterly Earnings ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
4 Analysts Have This To Say About Valneva ↗
 
Via Benzinga
News headline image
Expert Ratings For Valneva ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 6 Analyst Recommendations For Valneva ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 6 Takes On Valneva ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
12 Analysts Assess Valneva: What You Need To Know ↗
 
Via Benzinga
News headline image
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine ↗
Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Breaking Down Valneva: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot ↗
Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions. 
Via Benzinga
News headline image
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults ↗
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts. 
Via Benzinga
News headline image
European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
News headline image
Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study ↗
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion... 
Via Benzinga
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page